Despite an expanding array of advanced therapies for IBD, many patients with moderate to severe disease remain refractory to current options. Anti-tumor necrosis factor-like ligand 1A (TL1A) agents represent a promising new class targeting TL1A, a cytokine implicated in IBD pathogenesis. Experts review the current landscape and contextualize emerging data that suggest TL1A blockade may deliver meaningful clinical outcomes. As late-phase trials progress, clinicians should stay informed on this novel mechanism of action and its potential role in personalized treatment strategies for IBD.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Address:
- 523 Route 303
Pricing
97% of listed courses are free
34 of 35 courses listed here are free.
Collected from the provider’s public pages
Specialties served/covered
- Allergy & Clinical Immunology
- Anatomic & Clinical Pathology
- Communication & Shared Decision-Making
- Dermatology
- Gastroenterology
- General Pediatrics
- Hematology
- Medical Oncology
- Nephrology
- Obstetrics & Gynecology
- Ophthalmology
- Orthopaedic Surgery
- Psychotic Disorders
- Rheumatology
- Surgical Oncology
- Cross-Specialty
- GI & Liver
- Medical Subspecialties
- Ob/Gyn
- Oncology & Hematology
- Orthopedics
- Pathology & Lab
- Pediatrics
- Psychiatry
- Surgery
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Enduring / On-demand
- Credit · Up to 1 credit
- Commercial Support
-
ReleasedJan 30, 2026
-
Last day to claim creditJan 31, 2027 4 months left
-
Physicians’ Education Resource Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?
-
Vindico Medical Education, LLC TL1A Inhibition for IBD: Emerging Therapies at the Intersection of Inflammation and Fibrosis
-
PVI, PeerView Institute for Medical Education At the Crossroads of Inflammation and Fibrosis in Inflammatory Bowel Disease: The Promise of TL1A Inhibition
-
Paradigm Medical Communications, LLC New Paradigms Podcast: New and Emerging Mechanisms in the Treatment of SLE
-
Paradigm Medical Communications, LLC Discovering New Targets and Unique Strategies to Treat Sjögren s Disease
-
Paradigm Medical Communications, LLC Optimizing First-Line Treatment of Advanced RCC in the Era of Combination Therapies
